表紙
市場調查報告書

持續性上皮缺損(PED):至2030年的流行病學預測

Persistent Epithelial Defect (PED) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948137
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
持續性上皮缺損(PED):至2030年的流行病學預測 Persistent Epithelial Defect (PED) - Epidemiology Forecast - 2030
出版日期: 2020年06月01日內容資訊: 英文 100 Pages
簡介

持續性角膜上皮缺損,是由於在角膜損傷後10到14天內無法快速重新上皮和閉合而導致的。常在患有乾皰疹,神經營養性角膜病,糖尿病性角膜病等患者中發現。保護性隱形眼鏡(BCL)和人工淚液(AT)用於治療。

本報告提供主要7個國家關於(美國、日本、德國、西班牙、義大利、法國、英國)的至2030年的PED的流行病學展望調查,提供疾病概要,流行病學與患者數,各國流行病學,現在所進行的治療,未支援的需求等資訊提供做著。

目錄

第1章 主要調查結果

第2章 流行病學概要

第3章 摘要整理

第4章 組織

第5章 流行病學調查手法

第6章 疾病概要

  • 簡介
  • 臨床表現
  • 病因
  • 病理生理學
  • 診斷
    • 鑑別診斷

第7章 流行病學和患者數

    • 主要調查結果
  • 主要7個國家的總患病人數

第8章 主要7個國家的流行病學

  • 前提和根據
  • 美國
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第9章 現在所進行的治療

第10章 未支援的需求

第11章 SWOT分析

第12章 案例研究

第13章 主要意見領袖的意見

第14章 參考文獻

第15章 附錄

  • 調查手法

第16章 DelveInsight的服務內容

第17章 免責聲明

第18章 關於DelveInsight

目錄
Product Code: DIEI0942

DelveInsight's 'Persistent Epithelial Disease (PED)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Persistent Epithelial Disease, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Persistent Epithelial Disease (PED) Disease Understanding

Persistent Epithelial Disease, also known as persistent corneal epithelial defects (PEDs or PCEDs), results from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. PED is defined as "defects persisting for more than 2 weeks without improvement despite conventional treatment, such as non-preservative artificial tears or extended wear soft contact lenses" (Tsubota). PEDs commonly extend into the stromal layer, causing stromal melting, secondary ulceration, and stromal scarring. Also, an insult to the cornea resulting in an acute epithelial defect is a lesion that usually heals over the 7-14 days time frame. In contrast, a persistent epithelial defect is unable to close within this normal interval.

The normal corneal wound healing process can be disrupted from defective epithelial adhesion, limbal stem cell deficiency, surface trauma, medications, infections, and several other etiologies. Such defects are especially common in individuals with metaherpes, neurotrophic keratopathy, or diabetic keratopathy.

Some of the symptoms of PEDs are loss of corneal epithelial cells, delayed epithelialization post-injury, nonhealing epithelial defect and others which can be commonly due to Epithelial/limbal, inflammatory disease, Neurotrophic, mechanical causes, and others. Evaluating a PED involves instillation of fluorescein to monitor the size, location, and depth of the defect. A thorough physical exam should reveal findings such as inflammation in the anterior chamber, eyelid abnormalities, or decreased sensation of the cornea.

Persistent Epithelial Disease (PED) Epidemiology

The Persistent Epithelial Disease epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Persistent Epithelial Disease epidemiology segmented as the Total Incidence of Persistent Epithelial Disease, Etiology-specific cases. The report includes the Incident scenario of Persistent Epithelial Disease symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Persistent Epithelial Disease (PED) Epidemiology

The epidemiology segment also provides the Persistent Epithelial Disease (PED) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total Incident population of Persistent Epithelial Disease Associated in 7MM countries estimated to be 238,058 cases in 2017.

  • As per the estimates, the United States has the highest Incident population of Persistent Epithelial Disease.
  • Among the EU5 countries, Germany had the highest Incident population of Persistent Epithelial Disease. On the other hand, Spain had the lowest Incident population with 15,040 in 2017.

Scope of the Report:

  • Persistent Epithelial Disease (PED) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Persistent Epithelial Disease (PED) Epidemiology Report and Model provide an overview of the risk factors and global trends of Persistent Epithelial Disease (PED) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Persistent Epithelial Disease (PED) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Persistent Epithelial Disease
  • The report provides the segmentation of the Persistent Epithelial Disease (PED) epidemiology by Incident Cases of Persistent Epithelial Disease (PED) in 7MM
  • The report provides the segmentation of the Persistent Epithelial Disease (PED) epidemiology by Etiology -specific Incident Cases of Persistent Epithelial Disease (PED) in 7MM

Report Highlights:

  • 11-Year Forecast of Persistent Epithelial Disease (PED) epidemiology
  • 7MM Coverage
  • Total Incident Cases of Persistent Epithelial Disease (PED)
  • Incident Cases according to segmentation: Etiology-specific Incidence of Persistent Epithelial Disease (PED)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Persistent Epithelial Disease (PED)?
  • What are the key findings pertaining to the Persistent Epithelial Disease (PED) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Persistent Epithelial Disease (PED) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Persistent Epithelial Disease?
  • What are the currently available treatments of Persistent Epithelial Disease?

Reasons to buy:

The Persistent Epithelial Disease (PED) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Persistent Epithelial Disease (PED) market
  • Quantify patient populations in the global Persistent Epithelial Disease (PED) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Persistent Epithelial Disease (PED) therapeutics in each of the markets covered
  • Understand the magnitude of Persistent Epithelial Disease (PED) population by its Incidence cases
  • Understand the magnitude of Persistent Epithelial Disease (PED) population by its Etiology-specific cases
  • The Persistent Epithelial Disease (PED) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Persistent Epithelial Disease (PED) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

The review of the literature is not able to suggest the actual incidence of PED. However, the estimated incidence based on assumptions regarding the causes of PED helped to understand possible the number of cases of PED. Overall, the estimated number of PEDs per year in the United States is roughly 73,434 -99,465 cases (Wirostko et al., 2015). The total number of incidence of PEDs is less than 200,000 in the US and is therefore considered an orphan disease in this region (Vaidyanathan et al., 2019).

Table of Contents

1. Key Insights

2. Persistent Epithelial Defect (PED): Epidemiology Overview at a Glance

  • 2.1. Total Patient Share (%) Distribution of PED in 2017
  • 2.2. Total Patient Share (%) Distribution of PED in 2030

3. Executive summary

4. Organizations

5. Epidemiology Methodology

6. Persistent Epithelial Disease (PED): Disease Overview

  • 6.1. Introduction
  • 6.2. Clinical Presentation
  • 6.3. Etiology
  • 6.4. Pathophysiology
  • 6.5. Diagnosis
    • 6.5.1. Differential diagnosis

7. Epidemiology and Patient Population

    • 7.1.1. Key Findings
  • 7.2. Total Incident cases of Persistent epithelial defect in 7MM

8. 7MM Epidemiology of Persistent Epithelial Defects

  • 8.1. Assumptions and Rationale
  • 8.2. United States
    • 8.2.1. Total Incident cases of Persistent epithelial defect in the United States
    • 8.2.2. Etiology-specific cases of Persistent epithelial defect in the United States
  • 8.3. EU5 Countries
  • 8.4. Germany
    • 8.4.1. Total Incident cases of Persistent epithelial defect in Germany
    • 8.4.2. Etiology-specific cases of Persistent epithelial defect in Germany
  • 8.5. France
    • 8.5.1. Total Incident cases of Persistent epithelial defect in France
    • 8.5.2. Etiology-specific cases of Persistent epithelial defect in France
  • 8.6. Italy
    • 8.6.1. Total Incident cases of Persistent epithelial defect in Italy
    • 8.6.2. Etiology-specific cases of Persistent epithelial defect in Italy
  • 8.7. Spain
    • 8.7.1. Total Incident cases of Persistent epithelial defect in Spain
    • 8.7.2. Etiology-specific cases of Persistent epithelial defect in Spain
  • 8.8. UK
    • 8.8.1. Total Incident cases of Persistent epithelial defect in the United Kingdom
    • 8.8.2. Etiology-specific cases of Persistent epithelial defect in the United Kingdom
  • 8.9. Japan
    • 8.9.1. Total Incident cases of Persistent epithelial defect in Japan
    • 8.9.2. Etiology-specific cases of Persistent epithelial defect in Japan

9. Current Treatment Practices

10. Unmet Needs

11. SWOT Analysis

12. Case studies

  • 12.1. Refractory case of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops
  • 12.2. Treatment of Chronic Non-healing Neurotrophic Corneal Epithelial Defects with Thymosin Beta 4
  • 12.3. Healing Persistent Epithelial Defects: A Case Study
  • 12.4. Rapid healing of a persistent corneal epithelial defect (PCED) with autologous serum treatment

13. KOL Views

14. Bibliography

15. Appendix

  • 15.1. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

  • Table 1: Total Incident cases of Persistent epithelial defect in 7MM (2017-2030)
  • Table 2: Total Incident cases of Persistent epithelial defect in the US (2017-2030)
  • Table 3: Etiology-specific cases of Persistent epithelial defect in the US (2017-2030)
  • Table 4: Total Incident cases of Persistent epithelial defect in Germany (2017-2030)
  • Table 5: Etiology-specific cases of Persistent epithelial defect in Germany (2017-2030)
  • Table 6: Total Incident cases of Persistent epithelial defect in France (2017-2030)
  • Table 7: Etiology-specific cases of Persistent epithelial defect in France (2017-2030)
  • Table 8: Total Incident cases of Persistent epithelial defect in Italy (2017-2030)
  • Table 9: Etiology-specific cases of Persistent epithelial defect in Italy (2017-2030)
  • Table 10: Total Incident cases of Persistent epithelial defect in Spain (2017-2030)
  • Table 11: Etiology-specific cases of Persistent epithelial defect in Spain (2017-2030)
  • Table 12: Total Incident cases of Persistent epithelial defect in the UK (2017-2030)
  • Table 13: Etiology-specific cases of Persistent epithelial defect in the UK (2017-2030)
  • Table 14: Total Incident cases of Persistent epithelial defect in Japan (2017-2030)
  • Table 15: Etiology-specific cases of Persistent epithelial defect in Japan (2017-2030)

List of Figures

  • Figure 1: Epidemiology and Market Methodo+C3:D19logy
  • Figure 2:Depiction of a Persistent Epithelial Defect (PED)
  • Figure 3: Clinical features
  • Table 4: Clinical symptoms and their timely presentation
  • Table 5: Etiologies Of Persistent Corneal Epithelial Defect
  • Figure 6:Normal Epithelial Wound Healing Process
  • Figure 7: Growth Factors and Inflammatory Mediators Involved in the Epithelial Wound Healing Process
  • Figure 8: Total Incident cases of Persistent epithelial defect in 7MM (2017-2030)
  • Figure 9: Total Incident cases of Persistent epithelial defect in the US (2017-2030)
  • Figure 10: Etiology-specific cases of Persistent epithelial defect in the US (2017-2030)
  • Figure 11: Total Incident cases of Persistent epithelial defect in Germany (2017-2030)
  • Figure 12: Etiology-specific cases of Persistent epithelial defect in Germany (2017-2030)
  • Figure 13: Total Incident cases of Persistent epithelial defect in France (2017-2030)
  • Figure 14: Etiology-specific cases of Persistent epithelial defect in France (2017-2030)
  • Figure 15: Total Incident cases of Persistent epithelial defect in Italy (2017-2030)
  • Figure 16: Etiology-specific cases of Persistent epithelial defect in Italy (2017-2030)
  • Figure 17: Total Incident cases of Persistent epithelial defect in Spain (2017-2030)
  • Figure 18: Etiology-specific cases of Persistent epithelial defect in Spain (2017-2030)
  • Figure 19: Total Incident cases of Persistent epithelial defect in the UK (2017-2030)
  • Figure 20: Etiology-specific cases of Persistent epithelial defect in the UK (2017-2030)
  • Figure 21: Total Incident cases of Persistent epithelial defect in Japan (2017-2030)
  • Figure 22: Etiology-specific cases of Persistent epithelial defect in Japan (2017-2030)
  • Table 23: Stepwise Approach for the Management of Persistent Corneal Epithelial Defects
  • Figure 24: Unmet Needs
  • Figure 25: Market Drivers
  • Figure 26:Market Barriers